Azacitidine is a type of chemotherapy called a hypomethylating agent that interferes with the growth and spread of cancer cells in the body.
| SparkCures ID | 57 |
|---|---|
| Developed By | Celgene Corporation, a wholly owned subsidiary of Bristol Myers Squibb |
| Brand Name | Vidaza® |
| Generic Name | Azacitidine |
| Additional Names | 5-Azacytidine, Ladakamycin |
| Treatment Classifications |
View all active clinical trials around the US.
The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.
The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.
There are no resources, links or videos to display for this treatment.